YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]…
The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across various cancer indications. Additionally, t…
The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan On…
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLO…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ArriVent Biopharma Inc (Symbol: AVBP), where a total volume of 4,042 contracts has been traded thus far today, a contract…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astrazeneca (AZN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare fav…
(RTTNews) - ArriVent Biopharma, Inc. (AVBP) reported Loss for its full year of -$166.31 million The company's bottom line totaled -$166.31 million, or -$4.32 per share. This compares with -$80.49 million, or -$2.56 per share, last year. Ar…
This article first appeared on GuruFocus. Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Warning! GuruFocus has detected 5 Warning Signs with RKT. Is RKT fairly valued? Test your thesis with our free DCF c…
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalonta…
Bet_Noire / iStock via Getty Images Quick Read Stocks continued higher on Monday as the “Santa Claus” rally appears to be here. Small-caps were the big winner Monday as the Russell 2000 pushed higher again. Look for trading volume to reall…
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regul…
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,…
Exploring the Latest 13F Filing and Investment Adjustments Leon Cooperman (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into his investment moves during this period. Prior to found…
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1 Study for ARR-217 (MRG…
NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical company with a market capitalization of $805 million, announced Monday that topline data from its global pivotal Phase 3 FURVENT study of firm…
Investing.com - Clear Street has reiterated its Buy rating and $32.00 price target on ArriVent BioPharma (NASDAQ:AVBP), currently trading at $21.1, following the July 2 approval of competitor drug sunvozertinib (ZEGFROVY) for second-line E…
ArriVent BioPharma (NASDAQ:AVBP [https://seekingalpha.com/symbol/AVBP]) has priced [https://seekingalpha.com/pr/20154385-arrivent-announces-pricing-of-75-million-public-offering-of-common-stock-and-pre-funded]a securities offering to raise…
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today anno…
NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical company with a market capitalization of approximately $745 million, announced Tuesday its intention to offer $75 million of common stock and p…
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today anno…
Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company’s Phase 1b FURTHER trial evaluating firmonertinib in first-line EGFR PACC-po…
Investing.com - Clear Street initiated coverage on ArriVent BioPharma (NASDAQ:AVBP), which recently completed its IPO in January 2024, with a Buy rating and a $32.00 price target on Tuesday. The research firm cited firmonertinib, ArriVent’…
NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biotech company with a market capitalization of $863 million, announced follow-up data from its Phase 1b FURTHER trial showing 16.0 months median progression-fr…
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and…
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, t…
Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H 2025Expands ArriVent’s growin…
BEIJING, China, March 29, 2024--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of…